Press Сentre

Company news

Per page:
Moscow, July 14, 2020 – Chromis, a joint venture established by the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the signing of license and collaboration agreement with Brazil’s Axis BioTec to deliver the first Russian anti-COVID drug Avifavir to Brazil. Under the agreement Chromis will ...
14.07.2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, supported by the Russian Embassy in Guatemala held a video conference on July 10, 2020 with representatives of Latin American and Caribbean states to present the first Russian anti-COVID drug Avifavir. The regions are now facing an outbreak of ...
13.07.2020
RDIF and ChemRar have produced the first 100,000 courses of Avifavir In June Avifavir was delivered across Russia’s 35 regions More than 50 countries have expressed interest in importing Avifavir Moscow, July 2, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group produced the first 100,000 ...
02.07.2020
Moscow, June 11, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the delivery of the first batch of Avifavir to Russian hospitals. Clinics and pharmaceutical organizations in the Moscow, Leningrad, Novgorod, Kirov and Nizhny Novgorod regions, as well as in the Republic of ...
11.06.2020
Moscow, June 8, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group note increasingly frequent cases of fraud related to the sale of drugs based on the Favipiravir active ingredient.   Scammers have created a number of fake websites and are posting private adverts on well-known websites, selling ...
08.06.2020
Avifavir is one of the two registered COVID-19 drugs in the world Avifavir is the first drug registered in Russia that has demonstrated efficacy against COVID-19 in clinical trials Avifavir has become the first Favipiravir-based drug in the world approved for treatment of COVID-19 Moscow, June 3, 2020 - The Russian Direct Investment Fund ...
03.06.2020
Avifavir is the first direct-acting antiviral drug registered in Russia that has proven effective against COVID-19 in clinical trials Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19 Moscow, June 1, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ...
01.06.2020
Median elimination of the virus in four days compared to nine days with standard therapy, according to the study involving 60 patients Efficacy of the drug is above 80%, a criterion of a drug with high antiviral activity Russia’s Ministry of Health has approved the start of the final stage of clinical trials involving 330 patients, with ...
22.05.2020
Moscow, May 13, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the positive first interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19. According to the data received, 60% of the 40 ...
14.05.2020
Russia is set to test the antiviral drug Favipiravir as a treatment for COVID-19 following "excellent results" in China. The first batch of the drug is expected to arrive in a week, the state-run Tass news agency reported Tuesday. Favipiravir is also being tested in other countries as a potential treatment against the novel coronavirus, ...
07.04.2020
The drug has been used successfully in China to cure coronavirus patients Moscow, March 26, 2020 – The Supervisory Board of the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, has approved the creation of a Joint Venture (JV) with ChemRar Group aimed at the production of Favipiravir and other related innovative antiviral ...
26.03.2020
Avineuro Project from ChemRar Research Institute has finished the multicenter, randomized, double-blind, placebo-controlled pilot study of the efficacy, safety, and dosage of innovative drug AVN-101, (CD-008-0045), in patients with the generalized anxiety disorder (GAD). The study involved 129 patients. The results prove that the patient ...
27.11.2019